Efficacy of N-acetylcysteine in preventing amphotericin B induced acute kidney injury

No significant difference was observed in hypokalemia incidence between the groups (87.5 % in combination vs. 94.1 % in DAmB only groups).Conclusion: This clinical pilot study showed that NAC may be a promising anti-oxidant agent to decrease DAmB-induced AKI in febrile neutropenic patients.Keywords: Amphotericin

📌 3 Maddede Bu Makale

🎯

Amaç & Hipotez:Objectives: Previously, in an animal study we showed that N-acetylcysteine (NAC) could decrease deoxycholate amphotericin B (DAmB) induced renal tubular apoptosis.

📊

Temel Bulgular & Veri:In this clinical study, we aimed to evaluate the efficacy of NAC in preventing acute kidney injury (AKI) in febrile neutropenic patients with invasive pulmonary aspergillosis treated with DAmB.Patients and Methods: Thirty-three patients were included in the study. 17 patients were randomly placed into the DAmB group and 16 were randomly placed into the DAmB plus NAC group.Results: The characteristics of patients, durations and cumulative doses of DAmB, concurrent nephrotoxic drugs and basal serum creatinine (SCr) levels of patients were similar.

💡

Sonuç & Katkı:No significant difference was observed in hypokalemia incidence between the groups (87.5 % in combination vs. 94.1 % in DAmB only groups).Conclusion: This clinical pilot study showed that NAC may be a promising anti-oxidant agent to decrease DAmB-induced AKI in febrile neutropenic patients.Keywords: Amphotericin

🔬Tür:Araştırma Makalesi

📍Kapsam:Genişletilmiş Akademik Örneklem

⚙️Değişkenler:Amfoterisin B · Akut böbrek hasarı · N-asetilsistein

Özet

Objectives: Previously, in an animal study we showed that N-acetylcysteine (NAC) could decrease deoxycholate amphotericin B (DAmB) induced renal tubular apoptosis. In this clinical study, we aimed to evaluate the efficacy of NAC in preventing acute kidney injury (AKI) in febrile neutropenic patients with invasive pulmonary aspergillosis treated with DAmB.Patients and Methods: Thirty-three patients were included in the study. 17 patients were randomly placed into the DAmB group and 16 were randomly placed into the DAmB plus NAC group.Results: The characteristics of patients, durations and cumulative doses of DAmB, concurrent nephrotoxic drugs and basal serum creatinine (SCr) levels of patients were similar. Occurrence of a 1.5 fold or greater increase in the concentration of basal SCr and serum electrolytes were observed prospectively. The overall AKI was found in 13 patients (76.4%) in DAmB group and 6 patients (37.5%) in combination group (P = 0.024). No significant difference was observed in hypokalemia incidence between the groups (87.5 % in combination vs. 94.1 % in DAmB only groups).Conclusion: This clinical pilot study showed that NAC may be a promising anti-oxidant agent to decrease DAmB-induced AKI in febrile neutropenic patients.Keywords: Amphotericin

Abstract

Objectives: Previously, in an animal study we showed that N-acetylcysteine (NAC) could decrease deoxycholate amphotericin B (DAmB) induced renal tubular apoptosis. In this clinical study, we aimed to evaluate the efficacy of NAC in preventing acute kidney injury (AKI) in febrile neutropenic patients with invasive pulmonary aspergillosis treated with DAmB.Patients and Methods: Thirty-three patients were included in the study. 17 patients were randomly placed into the DAmB group and 16 were randomly placed into the DAmB plus NAC group.Results: The characteristics of patients, durations and cumulative doses of DAmB, concurrent nephrotoxic drugs and basal serum creatinine (SCr) levels of patients were similar. Occurrence of a 1.5 fold or greater increase in the concentration of basal SCr and serum electrolytes were observed prospectively. The overall AKI was found in 13 patients (76.4%) in DAmB group and 6 patients (37.5%) in combination group (P = 0.024). No significant difference was observed in hypokalemia incidence between the groups (87.5 % in combination vs. 94.1 % in DAmB only groups).Conclusion: This clinical pilot study showed that NAC may be a promising anti-oxidant agent to decrease DAmB-induced AKI in febrile neutropenic patients.Keywords: Amphotericin

Anahtar kelimeler

Amfoterisin B Akut böbrek hasarı N-asetilsistein Febril nötropeni

🔖

Bu Makaleye Atıf Yap

SENGEL, B. E., TİGEN, E. T., TOPTAS, T., ATAGUNDUZ, İ., TUGLULAR, A. T., ERGÖNÜL, M. O., ODABASI, Z. (2016). Efficacy of N-acetylcysteine in preventing amphotericin B induced acute kidney injury. Marmara Medical Journal, Cilt: 29 - Sayı: 2, 73–78. https://ajindex.com/articles/688343

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

Von Eiff M, Roos N, Schulten R, Hesse M, Zuhlsdorf M, van de Loo J. Pulmonary aspergillosis: early diagnosis improves survival. Respiration; International Review of Thoracic Diseases 1995; 62: 341-7. doi:10.1159/000196477 Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27: 603-18. doi: 10.1086/514704 Varlam DE, Siddiq MM, Parton LA, Rüssmann H. Apoptosis contributes to amphotericin B-induced nephrotoxicity. Antimicrob Agents Chemother 2001; 45: 679-85. doi: 10.1128/AAC.45.3.679-685.2001 Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agentinduced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180-4. doi: 0.1056/NEJM200007203430304 Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006; 354: 2773-82. doi: 10.1056/NEJMoa054209 Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003; 289: 553-8. doi: 10.1001/ jama.289.5.553 Odabasi Z, Karaalp A, Cermik H, et al. Reduction of amphotericin B-induced renal tubular apoptosis by N-acetylcysteine. Antimicrob Agents Chemother 2009; 53 -2. doi: 10.1128/AAC.00001-09
Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52: e56-93. doi 1093/cid/cir073 Khwaja A. KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Nephron Clin Pract 2012; 120: c179-84. doi:10.1159/000339789 Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60. doi: 10.1086/525258 Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update. Bone Marrow Transplant 2011; 46:709-18. doi: 10.1038/bmt.2010.175 Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 686-93. doi: 10.1086/319211 Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxici